A clinical trial update was recorded on September 18, 2026 for a study titled "GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer." The trial, registered as NCT07627191, is listed in the early phase 1 stage of development. Its current status is recruiting, meaning the study is actively enrolling participants at this time.
The trial is evaluating a GLP-1 receptor agonist administered alongside standard of care treatment. It is designed for patients with first-line, metastatic pancreatic, colorectal, or hepatocellular cancer. No results have been posted for this study as of the update date, and no efficacy or safety outcomes have been reported.
This entry reflects only the recruitment status and trial design details as registered. No conclusions about the treatment's benefit or risk can be drawn from a recruiting status alone. Further updates will depend on future postings to the trial registry as enrollment and study phases progress.
Readers interested in general background on glucagon can consult the compound overview for additional context.